Pancreatic Cancer Research

ResearcherQueen Mary University of LondonActive in the last 2 years

John F. Marshall

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0494-2295; OpenAlex author ID A5010733262. Sources: ClinicalTrials.gov.

Their work

Papers
13 (first author 0, last author 7)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 trial · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 3 papers

Papers 13

  1. The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells Against Pancreatic Cancer in an Immunocom… Last author DOI 10.3390/cancers17091534↗
  2. Pancreatic cancer metastasis is regulated by an eleven amino-acid sequence Last author DOI 10.64898/2025.12.07.692837↗
  3. Ephrin inhibition disrupts stromal-cancer crosstalk and reduces metastasis in pancreatic cancer Co-author DOI 10.64898/2025.12.10.693406↗
  4. Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancer. Last author DOI 10.1016/j.pan.2024.02.013↗
  5. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-19-2163↗
  6. Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2020.02.006↗
  7. Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. Last author DOI 10.7150/thno.38702↗
  8. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Last author DOI 10.1002/path.5320↗
  9. The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells. Co-author DOI 10.1158/1535-7163.mct-17-0671↗
  10. Pro-migratory and TGF-β-activating functions of αvβ6 integrin in pancreatic cancer are differentially regulated via an Eps8-dependent GTPase switch. Co-author DOI 10.1002/path.4923↗
  11. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13073-014-0105-3↗
  12. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1053/j.gastro.2013.07.025↗
  13. S100P-binding protein, S100PBP, mediates adhesion through regulation of cathepsin Z in pancreatic cancer cells. Co-author DOI 10.1016/j.ajpath.2011.12.031↗

Trials 1

  1. IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types Principal investigator NCT04285996↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nicholas Fraser Brown · 5 shared papers, 2020–2025 · strength 0.80
  2. Lauren C. Cutmore · 3 shared papers, 2020–2025 · strength 0.59
  3. Guillem Fuertes · 2 shared papers, 2025 · strength 0.51
  4. Yaohe Wang · 2 shared papers, 2020–2025 · strength 0.37
  5. Gareth J. Thomas · 2 shared papers, 2017–2025 · strength 0.34
  6. Hemant Mahendrakumar Kocher · 5 shared papers, 2012–2021 · strength 0.29
  7. Kate M. Moore · 3 shared papers, 2019–2021 · strength 0.28
  8. Eleni Maniati · 1 shared paper, 2025 · strength 0.28
  9. Renato B. Baleeiro · 1 shared paper, 2025 · strength 0.26
  10. Louisa S. Chard · 1 shared paper, 2025 · strength 0.26
  11. Zuoyi Zhao · 1 shared paper, 2025 · strength 0.26
  12. Deepak Raj · 2 shared papers, 2020–2021 · strength 0.23
  13. Shinelle Menezes · 1 shared paper, 2025 · strength 0.22
  14. Richard Philip Grose · 1 shared paper, 2025 · strength 0.22
  15. Angus J.M. Cameron · 1 shared paper, 2025 · strength 0.22
  16. Edward P. Carter · 1 shared paper, 2025 · strength 0.22
  17. Cerian L. Bolton · 1 shared paper, 2025 · strength 0.22
  18. Peter Schmid · 1 shared trial, 2016 · strength 0.19
  19. Claude Chelala · 4 shared papers, 2012–2019 · strength 0.18
  20. Claire S. Reader · 2 shared papers, 2019–2020 · strength 0.17
  21. John F. Maher · 1 shared paper, 2020 · strength 0.11
  22. Syed Haider · 2 shared papers, 2014–2019 · strength 0.11
  23. Aldo Scarpa · 2 shared papers, 2014–2019 · strength 0.11
  24. Sara Maria David Trabulo · 1 shared paper, 2020 · strength 0.10
  25. Y. K. Stella Man · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.